Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489592 | 0.92 | PPARA (0.52) | ADORA3PPARACYP2C9KDM4EHIF1A | |
| SCHEMBL489865 | 0.92 | MTOR (0.50) | ADORA3PPARAKDM4EHSD17B10LMNA | |
| SCHEMBL6689694 | 0.91 | ALDH1A1 (0.51) | PPARAKDM4ELMNAMAPTALDH1A1 | |
| SCHEMBL489360 | 0.90 | ALDH1A1 (0.50) | ADORA3KDM4EHSD17B10LMNAMAPT | |
| SCHEMBL17998996 | 0.89 | PPARA (0.50) | PPARAKDM4EHSD17B10LMNAMAPT | |
| SCHEMBL489737 | 0.89 | CACNA1C (0.43) | ADORA3PPARACYP2C9KDM4EHSD17B10 | |
| SCHEMBL489534 | 0.89 | NR1I2 (0.47) | ADORA3PPARACYP2C9KDM4EHIF1A | |
| SCHEMBL489564 | 0.87 | TBXA2R (0.54) | ADORA3PPARACYP2C9KDM4EHIF1A | |
| SCHEMBL489543 | 0.87 | PPARA (0.51) | ADORA3PPARACYP2C9KDM4EHIF1A | |
| SCHEMBL6060827 | 0.87 | PPARA (0.39) | ADORA3PPARACYP2C9KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470108-B1 | 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2016-08-24 | — | — | EP | claimed |
| EP-1542683-B1 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS INC (US) | 2013-01-09 | — | — | EP | claimed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | claimed |
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | DIAKRON PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | claimed |
| US-20060058355-A1 | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker | DITTRICH HOWARD C | 2006-03-16 | — | — | US | claimed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | claimed |
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | Knobbe, Martens, Olson & Bear, LLP | 2004-01-08 | — | — | US | claimed |
| EP-1470108-B1 | 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2016-08-24 | — | — | EP | disclosed |
| EP-1542683-B1 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS INC (US) | 2013-01-09 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | DIAKRON PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-7235570-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2007-06-26 | — | — | US | disclosed |
| US-20060058355-A1 | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker | DITTRICH HOWARD C | 2006-03-16 | — | — | US | disclosed |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2005-07-21 | — | — | US | disclosed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | disclosed |
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | Knobbe, Martens, Olson & Bear, LLP | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058355-A1 | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker | ACE, AGTR2, REN | ADORA3 710/4885PPARA 1356/4885CYP2C9 868/4885 |
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | AGTR2, ACE, AGTR1 | ADORA3 914/4885PPARA 1286/4885CYP2C9 899/4885 |
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | RYR2, ORAI1, RYR1 | ADORA3 896/4885PPARA 3043/4885CYP2C9 4051/4885 |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | RYR1, RYR2, ORAI1 | ADORA3 1153/4885PPARA 3351/4885CYP2C9 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.